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Bortezomib shows in vitro activity against a variety of lym-
phoid malignancies. It also is known to induce lytic cycle
gene expression in several EBV associated malignancies.
We compared its activity in killing isogenic EBV(+) and
EBV(-) Akata cells, two Burkitt's lymphoma cell lines, to
assess whether activation of viral lytic gene expression
might augment killing achieved in the absence of virus.
Cells were treated with bortezomib, ranging in concentra-
tion from 10 nM to 300 nM, for durations of 2, 24, 48,
and 96 hours. Cell viability was determined by trypan
blue exclusion, and changes in cell viability were charac-
terized by comparison to untreated Akata cells cultured in
parallel. The changes in cell viability resulting from the
presence of bortezomib were dose and time dependent.
Whereas low doses of bortezomib showed parallel killing
effects on EBV(+) and EBV(-) tumor cells, higher doses
appeared to be more toxic to EBV(+) cells. These higher
doses were associated with a rapid increase in viral DNA
copy number. In a murine xenograft model, we assessed
activation of lytic infection measured as a function of the
ability to concentrate [125I]FIAU. Uptake of [125I]FIAU
increased with increasing bortezomib dose in the range of
0.5–2.0 μg/g body mass at 30 hours post bortezomib
treatment. These findings are consistent with a dose-
response relationship for bortezomib and EBV lytic infec-
tion in EBV(+) Burkitt's lymphoma cell
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